Currently no consensus exists concerning the timing of upper endoscopy and the choice of antifungal therapy for patients infected with the human immunodeficiency virus who also have esophageal candidiasis.
The objective of this research was to determine the clinical and economic effects of alternative management strategies for these patients.
Decision analysis was used to evaluate the outcomes, costs, and cost-effectiveness of two strategies for the diagnostic workup and treatment of patients infected with the human immunodeficiency virus with dysphagia and/or odynophagia : (1) empiric-a strategy to treat all patients empirically with an oral antifungal agent for up to 4 weeks ; and (2) initial esophagogastroduodenoscopy (SGD) - a strategy to perform SGD on all patients and to treat only those with esophageal candidiasis with an oral antifungal agent for up to 4 weeks.
Mots-clés Pascal : SIDA, Virose, Infection, Candidose, Mycose, Oesophage, Fluconazole, Analyse coût efficacité, Economie santé, Chimiothérapie, Traitement, Homme, Antifongique, Immunopathologie, Oesophage pathologie, Appareil digestif pathologie
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Candidiasis, Mycosis, Esophagus, Cost efficiency analysis, Health economy, Chemotherapy, Treatment, Human, Antifungal agent, Immunopathology, Esophageal disease, Digestive diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0082245
Code Inist : 002B02S04. Création : 09/06/1995.